fashion -WSS

fashion

author：focus 2025-08-12 08:25:29 - browse：1196

DENVER — He could have been a rock star, a religious icon, the way ecstatic applause from thousands of attendees greeted the man dressed in a crisp, all-white suit as he strode onto a backlit stage. He was neither. This was Rick Doblin, the founder and evangelist of a movement to legalize psychedelic MDMA and bring the drug into mainstream medicine.

The scene in a Denver conference hall last week was a world away from the first conference Multidisciplinary Association for Psychedelic Studies (MAPS) held in 1990, when Doblin spoke alongside Timothy Leary — the ex-Harvard professor who popularized the phrase “turn on, tune in, and drop out.” That was just a few years after MDMA, also known as ecstasy, was criminalized, deemed a Schedule 1 drug “of no medical use.”

Now, as MAPS nears its goal of winning Food and Drug Administration approval for MDMA as a treatment for post-traumatic stress disorder, the perpetually smiling and energetic Doblin is basking in the adoration from both legions of “psychonauts” and unlikely yet powerful allies. “I literally love Rick Doblin,” the conservative Republican and former Texas governor Rick Perry told the audience in Denver.

It was a seemingly triumphant occasion. But even as Doblin is in sniffing distance of his lifelong quest, his once counter-cultural organization is grappling with the pressures of having to operate in the capitalist pharmaceutical sphere. MAPS was founded in 1986 as a nonprofit with deep-seated ideals. Doblin developed an “anti-patent” strategy, putting discoveries in the public domain so they couldn’t be claimed as intellectual property. He raised money to fund clinical trials of MDMA from like-minded wealthy donors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Biden’s NIH nominee is languishing in Congress

WSS

Nevada Republican Sam Brown launching another Senate bid, teeing up marquee race

As digital health tech proliferates, a new institute aims to cut through hype

‘Insidious 5’ topples 'Indiana Jones' before ‘Mission: Impossible’ launches

In early work, researchers turn to CRISPR to treat Alzheimer's

Sanders adds drug shortage policies to pandemic preparedness bill

Biden tests positive for Covid

entertainment

fashion

focus

Cancer drug shortages should be causing more outrage

See Ryan Reynolds, Hugh Jackman suited up in 1st look at 'Deadpool 3': Photo

Alkermes shareholders re

White House announces new plan to address the growing threat of xylazine in overdose crisis

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Sanders adds drug shortage policies to pandemic preparedness bill

FDA approval of Sarepta Duchenne genetic therapy gives me hope

How dance can help nurses traumatized by Covid

hotspot

In early work, researchers turn to CRISPR to treat Alzheimer's

Biden targets hefty hospital 'facility fees' that often surprise patients

DeSantis defends odds vs. Trump, despite early poll gap: 'We've worked really hard'

Custom gene therapy hints at new path for rare disease treatments

A public scorecard can help hold safety

Presidential fundraising highlights so far: Trump brings in more than DeSantis

hotspot

focus

explore

hotspot